Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity
This double-blind placebo-controlled study (n=18) explored the effects of two microdoses of LSD (13 & 26μg) on reward processing using a monetary incentive delay task. LSD increased three reward-related ERP components, reflecting increased hedonic, motivational, and affective processing of feedback, indicating that LSD increases reward-related activity in humans.
Authors
- Harriet de Wit
- Richard Lee
Published
Abstract
Renewed interest in classic psychedelics as treatments for psychiatric disorders warrants a deeper understanding of their neural mechanisms. Single, high doses of psychedelic drugs have shown promise in treating depressive disorders, perhaps by reversing deficits in reward processing in the brain. In addition, there are anecdotal reports that repeated ingestion of low doses of LSD, or “microdosing”, improve mood, cognition, and feelings of well-being. However, the effects of low doses of classic psychedelics on reward processing have not been studied. The current study examined the effects of two single, low doses of LSD compared to a placebo on measures of reward processing. Eighteen healthy adults completed three sessions in which they received a placebo (LSD-0), 13 μg LSD (LSD-13) and 26 μg LSD (LSD-26) in a within-subject, double-blind design. Neural activity was recorded while participants completed the electrophysiological monetary incentive delay task. Event-related potentials were measured during feedback processing (Reward-Positivity: RewP, Feedback-P3: FB-P3, and Late-Positive Potential: LPP). Compared to the placebo, LSD-13 increased RewP and LPP amplitudes for reward (vs. neutral) feedback, and LSD-13 and LSD-26 increased FB-P3 amplitudes for positive (vs. negative) feedback. These effects were unassociated with most subjective measures of drug effects. Thus, single, low doses of LSD (vs. placebo) increased three reward-related ERP components reflecting increased hedonic (RewP), motivational (FB-P3), and affective processing of feedback (LPP). These results constitute the first evidence that low doses of LSD increase reward-related brain activity in humans. These findings may have important implications for the treatment of depressive disorders.
Research Summary of 'Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity'
Introduction
Interest in classic psychedelics as treatments for psychiatric disorders has resurged, with prior clinical trials suggesting that single, relatively high doses of agents such as LSD or psilocybin can relieve mood and anxiety symptoms. Psychedelics principally act as serotonin (5-HT2A) agonists and, in the case of LSD, also engage dopamine systems implicated in reward processing. Deficits in neural reward processing are a prominent feature of depressive disorders, and electrophysiological markers of reward feedback (e.g., the Reward-Positivity, RewP) are often blunted in depression. Separately, anecdotal reports and popular interest in repeated very low doses of LSD (“microdosing”) claim improvements in mood and cognition, but controlled data on low-dose effects — especially on neural measures of reward — remain limited. Glazer and colleagues set out to test whether single, low doses of LSD alter neural indices of reward processing in healthy adults. Using scalp electroencephalography (EEG) and the electrophysiological monetary incentive delay (eMID) task, the investigators focused on three feedback-related event-related potentials (ERPs): the frontocentral Reward-Positivity (RewP), the parietal Feedback-P3 (FB-P3), and the Late-Positive Potential (LPP). The primary hypothesis was that single low doses of LSD (13 or 26 μg) would increase reward-related ERP amplitudes during feedback processing, consistent with effects that might be relevant to antidepressant mechanisms.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Glazer, J., Murray, C. H., Nusslock, R., Lee, R., & de Wit, H. (2023). Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity. Neuropsychopharmacology, 48(2), 418-426. https://doi.org/10.1038/s41386-022-01479-y
References (31)
Papers cited by this study that are also in Blossom
Preller, K. H., Herdener, M., Pokorny, T. et al. · Current Biology (2017)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · eLife (2018)
Dos Santos, R. G., Hallak, J. E., Baker, G. et al. · Journal of Psychopharmacology (2021)
Carhart-Harris, R. L., Roseman, L., Bolstridge, M. et al. · Scientific Reports (2017)
Kuypers, K. P. C. · Therapeutic Advances in Psychopharmacology (2020)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Perry, C. M., Malina, M. · Psychopharmacology (2021)
Yanakieva, S., Polychroni, N., Family, N. et al. · Psychopharmacology (2018)
Bershad, A. K., Schepers, S. T., Bremmer, M. P. et al. · Biological Psychiatry (2019)
Family, N., Maillet, E. L., Williams, L. T. J. et al. · Psychopharmacology (2019)
Show all 31 referencesShow fewer
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · European Neuropsychopharmacology (2020)
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)
Preller, K. H., Razi, A., Zeidman, P. et al. · PNAS (2019)
Lenz, C., Dolder, P. C., Lang, U. E. et al. · Acta Psychiatrica Scandinavica (2017)
Müller, F., Dolder, P. C., Schmidt, A. et al. · NeuroImage (2018)
Mueller, F., Lenz, C., Dolder, P. C. et al. · Translational Psychiatry (2017)
Kraehenmann, R., Preller, K. H., Scheidegger, M. et al. · Biological Psychiatry (2015)
Bershad, A. K., Preller, K. H., Lee, R. et al. · Biological Psychiatry (2020)
Polito, V., Stevenson, R. J. · PLOS ONE (2019)
Kanen, J. W., Luo, Q., Kandroodi, M. R. et al. · Psychological Medicine (2020)
Kraehenmann, R., Schmidt, A., Friston, K. et al. · NeuroImage (2015)
Grimm, O., Kraehenmann, R., Preller, K. H. et al. · European Neuropsychopharmacology (2018)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Roseman, L., Demetriou, L., Wall, M. B. et al. · Neuropharmacology (2018)
Bernasconi, F. ;., Schmidt, A. ;., Pokorny, T. ;. et al. · Cerebral Cortex (2013)
Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)
Bonson, K. R. · Neuropsychopharmacology (1996)
Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)
Martin, D. A., Nichols, C. D., Nichols, Á. C. D. · Current Topics in Behavioral Neurosciences (2017)
Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)
Olson, D. E. · ACS Pharmacology and Translational Science (2020)
Cited By (12)
Papers in Blossom that reference this study
Thuery, G., Crossen, F., Mc Loone, D. et al. · Therapeutic Advances in Psychopharmacology (2026)
Lima, G., Soares, C., Teixeira, M. et al. · Scientific Reports (2025)
Haggarty, C. J., Molla, H. M., Glazer, J. et al. · Psychedelic Medicine (2024)
Enriquez-Geppert, S,, Lietz, M. P., O'Higgins, F. · Philosophical Transactions of the Royal Society B (2024)
Hutten, N. R. P. W., Quaedflieg, C. W. E. M., Mason, N. L. et al. · Translational Psychiatry (2024)
Polito, V., Liknaitzky, P. · Journal of Psychopharmacology (2024)
Allen, N., Jeremiah, A., Murphy, R. et al. · Translational Psychiatry (2024)
Murphy, R. J., Godfrey, K., Shaw, A. D. et al. · BMC Psychiatry (2024)
Murray, C., Frohlich, J, Haggarty, C. J., Tare, I. et al. · Neuropsychopharmacology (2024)
Murphy, R., Muthukumaraswamy, S., De Wit, H. · Biological Psychiatry (2024)
Show all 12 papersShow fewer
Enriquez-Geppert, S,, Krc, J., O'Higgins, F., Lietz, M. P. · OSF Preprints (2023)
Zafar, R., Siegel, M., Harding, R. et al. · Frontiers in Psychiatry (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.